15 / 24
Treatment in 1L
% 2L
Rand Trials
Options
FOLFIRINOX
1
46%
mOS 4.4 months
No
Gem,
nab
-p + Gem
nab
-p + Gem
2
38%
mOS 5.3 months
NAPOLI trial
3
mOS 6.1 months
Nal-IRI + 5-FU/LV,
FOLFOX, 5-FU/LV
✓
Close monitoring 1L, CT scan every 8 weeks to 12 weeks
✓
We have available active 2L treatment regimens recommended by ESMO
4
and ASCO
5
guidelines
Is Second-Line Treatment in mPCA a Reality?
1. Conroy T, et al.
N Engl J Med.
2011;364(19):1817-1825. 2. Von Hoff DD, et al.
N Engl J Med.
2013;369(18):1691-1703. 3. Wang-Gillam A, et al.
Lancet
.
2016;387(10018):545-557. 4. ESMO Guidelines Committee.
Ann Oncol
. 2017;28(suppl4):iv157. 5. Sohal D, et al.
J Clin Oncol.
2018 May 23. [Epub ahead
of print].
My answer is
YES
2L, second-line; ASCO, American Society of Clinical Oncology; CT, computed tomography